- Optimi Health (OPTI) announced that preparations for a fourth-quarter launch of online sales are well underway
- In Q4 of this year, Optimi plans to launch a dedicated sales channel on a proven direct-to-consumer platform through a partnership with VitaSave
- Optimi has also begun working with Colony Digital to build consumer awareness
- Optimi is developing a sophisticated mushroom brand that focuses on the health and wellness markets
- Optimi Health Corp. (OPTI) opened trading at C$0.72 per share
Optimi Health (OPTI) has announced that preparations for a fourth-quarter launch of online sales are well underway.
Dane Stevens, Chief Marketing Officer of Optimi Health notes,
“As we near the upcoming launch of our online sales we are excited about transforming Optimi into a vertically integrated and actively revenue-generating company. It’s important for both Optimi and our shareholders to utilize new-found revenues to spur value creation and help fund our ongoing initiatives. We remain committed to driving innovation, executing our upcoming clinical trials, and ultimately growing our footprint throughout North America and beyond. An aggressive product sales strategy has long been a part of our blueprint to achieve these goals.
Optimi is focused on designing products that will allow consumers to capture the amazing benefits of mushrooms in easy-to-use ways” adds Optimi’s Stevens. “We believe our exceptional capsules and vegan protein formulations are a major step forwards in bringing superior functional mushrooms into the mainstream across North America.”
In Q4 of this year, Optimi plans to launch a dedicated sales channel on a proven direct-to-consumer platform through a partnership with VitaSave. At launch, the business will focus on the Canadian market with plans to enter the US market in 2022.
Optimi will continue to develop additional product innovations to complement and expand upon the launch offerings.
Optimi has also begun working with Colony Digital, a subsidiary of online publishers Daily Hive, for the roll-out of upcoming marketing initiatives and consumer awareness strategies. To further support the launch, Optimi has retained the Vancouver office of Citizen Relations to drive enhanced awareness across the Canadian consumer market landscape.
Optimi is developing a sophisticated mushroom brand that focuses on the health and wellness markets. Optimi intends to cultivate, extract, process and distribute high-quality functional mushroom products at its two facilities comprising a total of 20,000 square feet nearing completion in Princeton, British Columbia.
Optimi has received a research exemption under Health Canada Food and Drug Regulations (FDR) for the use of Psilocybin and Psilocin for scientific purposes via its wholly-owned subsidiary Optimi Labs Inc. Optimi has also applied for a dealer’s license under Canada’s Narcotic Control Regulations governing the possession, distribution, sale, laboratory analysis of and research and development of Psilocybin and Psilocin formulations.
Optimi Health Corp. (OPTI) opened trading at C$0.72 per share.
